Long-Term Androgen Deprivation Better Than Short-Term in Prostate Cancer
the Cancer Therapy Advisor take:
Two years of adjuvant androgen deprivation therapy (ADT) combined with high-dose radiotherapy improves control and overall survival in high-risk patients with prostate cancer compared to short-term ADT, according to a recent study published in The Lancet Oncology.
Spanish researchers led by Almudena Zapatero, PhD, of the Hospital Universitario de la Princesa conducted an open-label, multicenter, phase 3 randomized controlled trial from November 2005 to December 2010. They examined 178 patients with prostate cancer who received short-term ADT and 177 who received long-term ADT.
Median follow-up was 63 months, and the primary endpoint was biochemical disease-free survival.
The researchers found that 5-year biochemical disease-free survival, 5-year overall survival and 5-year metastasis-free survival were all significantly better in patients who received long-term ADT compared to short-term.
Additionally, they found that the effect of long-term ADT on survival was more evident in patients with high-risk disease compared to low-risk patients.
Two years of adjuvant ADT combined with high-dose radiotherapy improves survival in prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed